Onvansertib for the Treatment of Recurrent or Refractory Chronic Myelomonocytic Leukemia
Status:
Not yet recruiting
Trial end date:
2026-12-30
Target enrollment:
Participant gender:
Summary
This phase I trial evaluates the safety, effectiveness, and best dose of onvansertib for the
treatment of patients with chronic myelomonocytic leukemia that has come back (recurrent) or
that does not respond to treatment (refractory). Onvansertib is a drug that binds to and
inhibits an enzyme called PLK1, preventing cancer cell proliferation and causing cell death.